These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36810856)

  • 1. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
    Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
    Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
    Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
    Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
    Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
    Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
    J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
    J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
    Ninomaru T; Hata A; Hara S; Komatsu M
    Thorac Cancer; 2022 Aug; 13(16):2394-2397. PubMed ID: 35793695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report.
    Yang Z; Lin Y; Wang H
    J Int Med Res; 2021 Aug; 49(8):3000605211035005. PubMed ID: 34396834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
    Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
    Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.
    Jing M; He X; Cai CZ; Ma QZ; Li K; Zhang BX; Yin Y; Shi MS; Wang YS
    Biochem Biophys Res Commun; 2023 Nov; 681():218-224. PubMed ID: 37783120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.